U.S. Diabetes Pipeline Outlook : Market Research Report

U.S. Diabetes Pipeline Outlook

Published: Nov. 22, 2006 - 72 Pages

1. Executive Summary
1. Executive Summary
1. Introduction

2. Market Introduction
    1. Research Scope and Methodology
        1. Scope and Segmentation
        2. Research Methodology
    2. Diabetes Overview
        1. Introduction
        2. Types of Diabetes
        3. Prevalence
        4. Incidence
        5. Current Treatment
    3. Pipeline Competitive Analysis
        1. Introduction
        2. Key Pipeline Companies
        3. Areas of Opportunity

3. GLP-1 Agonists
    1. Introduction
        1. GLP-1 Agonist Dynamics
    2. GLP-1 Agonists Pipeline Analysis
        1. Byetta - Amylin & Eli Lilly
        2. GLP-1 Agonist Pipeline

4. Pulmonary Insulin
    1. Introduction
        1. Pulmonary Insulin Dynamics
    2. Pulmonary Insulin Analysis
        1. Exubera - Pfizer & Nektar
        2. Pulmonary Insulin Pipeline

5. DPP-IV Inhibitors
    1. Introduction
        1. DPP-IV Dynamics
    2. DPP-IV Pipeline Analysis
        1. Pipeline Analysis
6. PPAR Modulators
    1. Introduction
        1. PPAR Dynamics
    2. PPAR Pipeline Analysis
        1. PPAR Pipeline
        2. Discontinued PPAR Modulators

7. Other Pipeline Efforts
    1. Introduction
        1. Other Development Efforts
    2. Pipeline Overviews
        1. Other Insulin Pipeline
        2. Other OAD Pipeline
        3. Other IAD Pipeline

8. Appendix
    1. Decision Support Databases
        1. Incidence of Diabetes
        2. Prevalence of Diabetes
        3. Diabetes Prevalence as a Percentage of Total Population
        4. Diabetes Foot Ulcer Prevalence as a Percentage of Total Population
        5. Total Population

Abstract

This research service covers the pharmaceutical industry development pipeline for diabetes mellitus in the United States, with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs, injectables, and insulins other than pulmonary. Product Analysis charts are included for those products in Phase III clinical trials.

Research Overview

Diabetes is a growing epidemic in the United States, with the number of diagnosed people with the disease more than doubling over the past 15 years. As current treatments leave a large amount of room for improvement with an area of unmet medical need, a multitude of companies are working on new types of drug products to better help control and prevent diabetes and its subsequent complications. New pipeline technologies have the ability to improve upon current diabetes therapy and create new treatment options and pathways for patients and physicians.

This research service provides an overview of the drug products in clinical development for the treatment of Diabetes in the United States. Major trends and technologies are discussed as well as highlighting leading areas of development and late stage compounds. The products covered are segmented in to the following categories:

GLP-1 Agonists
Pulmonary Insulin
DPP-IV Inhibitors
PPAR Modulators
Other Pipeline Effort

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

U.S. Diabetes Pipeline Outlook

Table of Contents

Abstract